Biogen (BIIB) ROIC: History & Chart

Name: Biogen Inc. (BIIB) Return on Invested Capital (ROIC) — historical time series
Creator: TGMCharts

Compare

Biogen Inc.(BIIB)

Drug Manufacturers - General · Cambridge, MA

$213.70-7.13 (-3.23%)

Delayed quote: Sep 8, 2026, 2:55 PM EDT

Compare

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

BIIB Return on Invested Capital (ROIC) Metrics

RETURN ON INVESTED CAPITAL (ROIC)

4.28%

RETURN ON INVESTED CAPITAL (ROIC) AVG TTM

6.49%

RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y

7.47%

RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y

8.62%

RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y

14.09%

RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y

15.62%

RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y

14.04%

CURRENT VS TTM AVG

-34.04%

CURRENT VS 3Y AVG

-42.66%

CURRENT VS 5Y AVG

-50.30%

CURRENT VS 10Y AVG

-69.61%

CURRENT VS 15Y AVG

-72.59%

CURRENT VS 20Y AVG

-69.50%

SECTOR MEDIAN · HEALTHCARE

8.75%

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

-51.03%

vs the sector median at left

NAME	MARKET CAP	RETURN ON INVESTED CAPITAL (ROIC)	TTM	3Y	5Y
Biogen Inc. (BIIB)	$31.58B	4.28%	6.49%	7.47%	8.62%
DexCom, Inc. (DXCM)vs ›	$32.07B	21.71%	13.47%	11.13%	9.67%
Zoetis Inc. (ZTS)vs ›	$31.04B	21.63%	21.87%	20.30%	19.27%
Centene Corp. (CNC)vs ›	$32.22B	-12.90%	-4.21%	-0.54%	0.75%
ResMed Inc. (RMD)vs ›	$32.26B	19.18%	19.41%	18.01%	17.23%
GE HealthCare Technologies Inc. (GEHC)vs ›	$30.35B	6.94%	7.96%	8.07%	9.18%
Waters Corporation (WAT)vs ›	$30.19B	1.34%	18.13%	20.89%	23.01%
Medline Inc. (MDLN)vs ›	$29.75B	4.05%	6.03%	5.27%	5.27%
Alcon Inc. (ALC)vs ›	$33.80B	3.25%	4.01%	3.42%	2.30%
Alnylam Pharmaceuticals, Inc. (ALNY)vs ›	$35.17B	24.71%	4.06%	-7.50%	-13.90%

NAME

MARKET CAP

RETURN ON INVESTED CAPITAL (ROIC)

TTM

Biogen Inc. (BIIB)

$31.58B

4.28%

6.49%

7.47%

8.62%

DexCom, Inc. (DXCM)vs ›

$32.07B

21.71%

13.47%

11.13%

9.67%

Zoetis Inc. (ZTS)vs ›

$31.04B

21.63%

21.87%

20.30%

19.27%

Centene Corp. (CNC)vs ›

$32.22B

-12.90%

-4.21%

-0.54%

0.75%

ResMed Inc. (RMD)vs ›

$32.26B

19.18%

19.41%

18.01%

17.23%

GE HealthCare Technologies Inc. (GEHC)vs ›

$30.35B

6.94%

7.96%

8.07%

9.18%

Waters Corporation (WAT)vs ›

$30.19B

1.34%

18.13%

20.89%

23.01%

Medline Inc. (MDLN)vs ›

$29.75B

4.05%

6.03%

5.27%

Alcon Inc. (ALC)vs ›

$33.80B

3.25%

4.01%

3.42%

2.30%

Alnylam Pharmaceuticals, Inc. (ALNY)vs ›

$35.17B

24.71%

4.06%

-7.50%

-13.90%

Return on Invested Capital (ROIC) Formula & Definition

ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)

Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.

Return on Invested Capital (ROIC) FAQ

What is the return on invested capital (ROIC) for Biogen Inc. (BIIB)?

The return on invested capital (ROIC) for BIIB stock is 4.28%.

Is Biogen Inc.'s return on invested capital (ROIC) high or low?

The return on invested capital (ROIC) of 4.28% is 50% below its 5-year average of 8.62%, near the low end of its 5-year range (4.28%–12.98%).

What is the TTM average return on invested capital (ROIC) for Biogen Inc. (BIIB)?

The TTM average return on invested capital (ROIC) for BIIB stock is 6.49%.

What is the 3Y average return on invested capital (ROIC) for Biogen Inc. (BIIB)?

The 3Y average return on invested capital (ROIC) for BIIB stock is 7.47%.

What is the 5Y average return on invested capital (ROIC) for Biogen Inc. (BIIB)?

The 5Y average return on invested capital (ROIC) for BIIB stock is 8.62%.

What is the 10Y average return on invested capital (ROIC) for Biogen Inc. (BIIB)?

The 10Y average return on invested capital (ROIC) for BIIB stock is 14.09%.

What is the 15Y average return on invested capital (ROIC) for Biogen Inc. (BIIB)?

The 15Y average return on invested capital (ROIC) for BIIB stock is 15.62%.

What is the 20Y average return on invested capital (ROIC) for Biogen Inc. (BIIB)?

The 20Y average return on invested capital (ROIC) for BIIB stock is 14.04%.

DATE	RETURN ON INVESTED CAPITAL (ROIC)
2026-06-30	4.28%
2026-03-31	5.44%
2025-12-31	6.62%
2025-09-30	7.96%
2025-06-30	8.15%
2025-03-31	7.53%
2024-12-31	7.56%
2024-09-30	7.38%
2024-06-30	7.03%
2024-03-31	8.27%
2023-12-31	7.97%
2023-09-30	8.23%
2023-06-30	10.46%
2023-03-31	11.56%
2022-12-31	11.19%
2022-09-30	9.50%
2022-06-30	8.86%
2022-03-31	10.25%
2021-12-31	12.98%
2021-09-30	9.29%
2021-06-30	10.42%
2021-03-31	14.41%
2020-12-31	17.52%
2020-09-30	25.33%
2020-06-30	27.76%
2020-03-31	27.25%
2019-12-31	24.66%
2019-09-30	21.85%
2019-06-30	22.25%
2019-03-31	18.99%
2018-12-31	20.30%
2018-09-30	15.14%
2018-06-30	15.62%
2018-03-31	14.04%
2017-12-31	14.49%
2017-09-30	18.00%
2017-06-30	18.22%
2017-03-31	19.33%
2016-12-31	19.83%
2016-09-30	20.73%
2016-06-30	21.19%
2016-03-31	21.63%
2015-12-31	21.83%
2015-09-30	20.41%
2015-06-30	24.85%
2015-03-31	24.97%
2014-12-31	24.56%
2014-09-30	21.65%
2014-06-30	19.72%
2014-03-31	18.25%
2013-12-31	18.71%
2013-09-30	17.70%
2013-06-30	16.92%
2013-03-31	16.58%
2012-12-31	15.23%
2012-09-30	15.95%
2012-06-30	16.36%
2012-03-31	15.39%
2011-12-31	15.68%
2011-09-30	15.77%
2011-06-30	12.90%
2011-03-31	13.26%
2010-12-31	12.71%
2010-09-30	14.26%
2010-06-30	16.19%
2010-03-31	12.37%
2009-12-31	12.09%
2009-09-30	10.58%
2009-06-30	10.41%
2009-03-31	11.66%
2008-12-31	10.93%
2008-09-30	10.28%
2008-06-30	8.79%
2008-03-31	7.94%
2007-12-31	6.87%
2007-09-30	6.62%
2007-06-30	9.81%
2007-03-31	3.00%
2006-12-31	3.04%
2006-09-30	2.44%
2006-06-30	1.16%
2006-03-31	2.58%
2005-12-31	1.90%
2005-09-30	1.63%
2005-06-30	1.86%
2005-03-31	1.30%
2004-12-31	0.28%
2004-09-30	-13.00%
2004-06-30	-12.64%
2004-03-31	-11.71%
2003-12-31	-10.16%
2003-09-30	8.94%
2003-06-30	9.58%

DATE

RETURN ON INVESTED CAPITAL (ROIC)

2026-06-30

4.28%

2026-03-31

5.44%

2025-12-31

6.62%

2025-09-30

7.96%

2025-06-30

8.15%

2025-03-31

7.53%

2024-12-31

7.56%

2024-09-30

7.38%

2024-06-30

7.03%

2024-03-31

8.27%

2023-12-31

7.97%

2023-09-30

8.23%

2023-06-30

10.46%

2023-03-31

11.56%

2022-12-31

11.19%

2022-09-30

9.50%

2022-06-30

8.86%

2022-03-31

10.25%

2021-12-31

12.98%

2021-09-30

9.29%

2021-06-30

10.42%

2021-03-31

14.41%

2020-12-31

17.52%

2020-09-30

25.33%

2020-06-30

27.76%

2020-03-31

27.25%

2019-12-31

24.66%

2019-09-30

21.85%

2019-06-30

22.25%

2019-03-31

18.99%

2018-12-31

20.30%

2018-09-30

15.14%

2018-06-30

15.62%

2018-03-31

14.04%

2017-12-31

14.49%

2017-09-30

18.00%

2017-06-30

18.22%

2017-03-31

19.33%

2016-12-31

19.83%

2016-09-30

20.73%

2016-06-30

21.19%

2016-03-31

21.63%

2015-12-31

21.83%

2015-09-30

20.41%

2015-06-30

24.85%

2015-03-31

24.97%

2014-12-31

24.56%

2014-09-30

21.65%

2014-06-30

19.72%

2014-03-31

18.25%

2013-12-31

18.71%

2013-09-30

17.70%

2013-06-30

16.92%

2013-03-31

16.58%

2012-12-31

15.23%

2012-09-30

15.95%

2012-06-30

16.36%

2012-03-31

15.39%

2011-12-31

15.68%

2011-09-30

15.77%

2011-06-30

12.90%

2011-03-31

13.26%

2010-12-31

12.71%

2010-09-30

14.26%

2010-06-30

16.19%

2010-03-31

12.37%

2009-12-31

12.09%

2009-09-30

10.58%

2009-06-30

10.41%

2009-03-31

11.66%

2008-12-31

10.93%

2008-09-30

10.28%

2008-06-30

8.79%

2008-03-31

7.94%

2007-12-31

6.87%

2007-09-30

6.62%

2007-06-30

9.81%

2007-03-31

3.00%

2006-12-31

3.04%

2006-09-30

2.44%

2006-06-30

1.16%

2006-03-31

2.58%

2005-12-31

1.90%

2005-09-30

1.63%

2005-06-30

1.86%

2005-03-31

1.30%

2004-12-31

0.28%

2004-09-30

-13.00%

2004-06-30

-12.64%

2004-03-31

-11.71%

2003-12-31

-10.16%

2003-09-30

8.94%

2003-06-30

9.58%

Return on Invested Capital (ROIC): 4.28%

BIIB Return on Invested Capital (ROIC)

BIIB Average Return on Invested Capital (ROIC) Chart

BIIB Current vs Average Return on Invested Capital (ROIC) Chart

BIIB Return on Invested Capital (ROIC) Metrics

BIIB Competitors' Return on Invested Capital (ROIC)

Capital Efficiency

Return on Invested Capital (ROIC) Formula & Definition

Return on Invested Capital (ROIC) FAQ

BIIB Return on Invested Capital (ROIC) History

Related Metrics